Steen D Kristensen1, Kristina G Laut2, Jean Fajadet3, Zuzana Kaifoszova4, Petr Kala5, Carlo Di Mario6, William Wijns7, Peter Clemmensen8, Vaja Agladze9, Loizos Antoniades10, Khalid F Alhabib11, Menko-Jan De Boer12, Marc J Claeys13, Dan Deleanu14, Dariusz Dudek15, Andrejs Erglis16, Martine Gilard17, Omer Goktekin18, Giulio Guagliumi19, Thorarinn Gudnason20, Kim Wadt Hansen21, Kurt Huber22, Stefan James23, Tomáš Janota24, Siobhan Jennings25, Olli Kajander26, John Kanakakis27, Kiril K Karamfiloff28, Sasko Kedev29, Ran Kornowski30, Peter F Ludman31, Béla Merkely32, Davor Milicic33, Ruslan Najafov34, Francesca A Nicolini35, Marko Noč36, Miodrag Ostojic37, Hélder Pereira38, Dragana Radovanovic39, Manel Sabaté40, Mohamed Sobhy41, Maxim Sokolov42, Martin Studencan43, Ibrahim Terzic44, Steffen Wahler45, Petr Widimsky46. 1. Department of Cardiology, Aarhus University Hospital, Brendstrupgaardsvej 100, Skejby, DK-8200 Aarhus N, Denmark steendk@dadlnet.dk. 2. Department of Cardiology, Aarhus University Hospital, Brendstrupgaardsvej 100, Skejby, DK-8200 Aarhus N, Denmark. 3. Clinique Pasteur, Toulouse, France. 4. Stent for Life Initiative, UK European Association of Percutaneous Cardiovascular Interventions (EAPCI), The European Heart House, France. 5. Department of Internal Cardiovascular Medicine, Masaryk University and University Hospital Brno, Brno, Czech Republic. 6. Cardiovascular Biomedical Research Unit, Royal Brompton Hospital, London, UK. 7. Cardiovascular Center Aalst, OLV Hospital, Aalst, Belgium. 8. Department of Cardiology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark. 9. SFL Contact Person in Geogia, 0105, Tbilisi, Georgia. 10. Department of Cardiology, Larnaca General Hospital, Larnaca, Cyprus. 11. Department of Cardiac Sciences, King Fahad Cardiac Center, College of Medicine, King Saud University, Riyadh, Kingdom of Saudi Arabia. 12. Department of Cardiology, UMC St Radboud Nijmegen, Hearth Lung Center, Nijmegen, The Netherlands. 13. Department of Cardiology, University Hospital Antwerp, Antwerp, Belgium. 14. Cardiovascular Diseases Institute 'C.C.Iliescu', Bucharest, Romania. 15. Department of Cardiology and Cardiovascular Interventions, University Hospital, Jagiellonian University, Krakow, Poland. 16. University of Latvia, Pauls Stradins Clinical University Hospital, Riga, Latvia. 17. Department of Cardiology, CHRU La Cavale Blance, Brest Cedex, France. 18. Department of Cardiology, Medical Faculty, Bezmialem Vakif University, Istanbul, Turkey. 19. Division of Cardiology, Cardiovascular Department, Ospedali Riuniti, Bergamo, Italy. 20. Department of Cardiology and Cardiovascular Research Center, Landspitali, University Hospital of Iceland, Reykjavik, Iceland. 21. Department of Cardiology, Copenhagen University Hospital Gentofte, Hellerup, Denmark. 22. 3rd Department of Internal Medicine, Cardiology and Emergency Medicine, Wilhelminen Hospital, Vienna, Austria. 23. Department of Cardiology and Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden. 24. University Hospital, 1st Medical School, Charles University Prague, Prague, Czech Republic. 25. Department of Public Health, Health Service Executive, Dublin, Ireland. 26. Heart Center Co., Tampere University Hospital, Tampere, Finland. 27. Alexandra Hospital, Department of Clinical Therapeutics, University of Athens, Athens, Greece. 28. Department of Cardiology, University Hospital 'St. Ekaterina', Sofia, Bulgaria. 29. University Clinic of Cardiology, Department of Interventional Cardiology, University St. Cyril and Methodius, Skopje, Marcedonia. 30. Department of Cardiology, Belinson and Hasharon Hospitals, Petach Tikva and 'Sackler' Facultu of Medicine, Tel Aviv University, Tel Aviv, Israel. 31. Cardiology Department, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK. 32. Semmelweis University Heart Center, Budapest, Hungary. 33. Department of Cardiovascular Diseases, University of Zagreb School of Medicine, University Hospital Centre Zagreb, Zagreb, Croatia. 34. Myocardial Infarction Department, Cardiology Research Institute, Baku, Azerbaijan. 35. Division of Cardiology, Department of Internal Medicine, Ospedale di Stato, San Marino, Republic of San Marino. 36. University Medical Center, Ljubljana, Slovenia. 37. Department of Cardiology, Institute for Cardiovascular Diseases, Clinical Centre of Serbia, Belgrade, Serbia. 38. SFL, Portugal Champion, Association of Cardiovascular Intervention, Portugese Society of Cardiology, Lisbon, Portugal. 39. AMIS Plus Data Center, Institute of Social and Preventive Medicine University of Zurich, Zurich, Switzerland. 40. Department of Cardiology, Clinic Thorax Institute, Hospital Clinic de Barcelona, Barcelona, Spain. 41. SFL Egypt Champion, Faculty of Medicine, Alexandria University, Alexandria, Egypt. 42. National Scientific Center 'the MD Strazhesko Institute of Cardiology' Academy of Medical Science of Ukraine, Kiev, Ukraine. 43. Cardiac Centre, University Hospital of J.A. Reiman, Prešov, Slovakia. 44. BH Heart Center Tuzla, Bosnia and Herzegovina. 45. Department of Health Economics, Medical School Hamburg, Hamburg, Germany. 46. Cardiocenter, Third Faculty of Medicine, Charles University Prague, Prague, Czech Republic.
Abstract
AIMS: Primary percutaneous coronary intervention (PPCI) is the preferred reperfusion therapy in ST-elevation myocardial infarction (STEMI). We conducted this study to evaluate the contemporary status on the use and type of reperfusion therapy in patients admitted with STEMI in the European Society of Cardiology (ESC) member countries. METHODS AND RESULTS: A cross-sectional descriptive study based on aggregated country-level data on the use of reperfusion therapy in patients admitted with STEMI during 2010 or 2011. Thirty-seven ESC countries were able to provide data from existing national or regional registries. In countries where no such registries exist, data were based on best expert estimates. Data were collected on the use of STEMI reperfusion treatment and mortality, the numbers of cardiologists, and the availability of PPCI facilities in each country. Our survey provides a brief data summary of the degree of variation in reperfusion therapy across Europe. The number of PPCI procedures varied between countries, ranging from 23 to 884 per million inhabitants. Primary percutaneous coronary intervention and thrombolysis were the dominant reperfusion strategy in 33 and 4 countries, respectively. The mean population served by a single PPCI centre with a 24-h service 7 days a week ranged from 31 300 inhabitants per centre to 6 533 000 inhabitants per centre. Twenty-seven of the total 37 countries participated in a former survey from 2007, and major increases in PPCI utilization were observed in 13 of these countries. CONCLUSION: Large variations in reperfusion treatment are still present across Europe. Countries in Eastern and Southern Europe reported that a substantial number of STEMI patients are not receiving any reperfusion therapy. Implementation of the best reperfusion therapy as recommended in the guidelines should be encouraged. Published on behalf of the European Society of Cardiology. All rights reserved.
AIMS: Primary percutaneous coronary intervention (PPCI) is the preferred reperfusion therapy in ST-elevation myocardial infarction (STEMI). We conducted this study to evaluate the contemporary status on the use and type of reperfusion therapy in patients admitted with STEMI in the European Society of Cardiology (ESC) member countries. METHODS AND RESULTS: A cross-sectional descriptive study based on aggregated country-level data on the use of reperfusion therapy in patients admitted with STEMI during 2010 or 2011. Thirty-seven ESC countries were able to provide data from existing national or regional registries. In countries where no such registries exist, data were based on best expert estimates. Data were collected on the use of STEMI reperfusion treatment and mortality, the numbers of cardiologists, and the availability of PPCI facilities in each country. Our survey provides a brief data summary of the degree of variation in reperfusion therapy across Europe. The number of PPCI procedures varied between countries, ranging from 23 to 884 per million inhabitants. Primary percutaneous coronary intervention and thrombolysis were the dominant reperfusion strategy in 33 and 4 countries, respectively. The mean population served by a single PPCI centre with a 24-h service 7 days a week ranged from 31 300 inhabitants per centre to 6 533 000 inhabitants per centre. Twenty-seven of the total 37 countries participated in a former survey from 2007, and major increases in PPCI utilization were observed in 13 of these countries. CONCLUSION: Large variations in reperfusion treatment are still present across Europe. Countries in Eastern and Southern Europe reported that a substantial number of STEMI patients are not receiving any reperfusion therapy. Implementation of the best reperfusion therapy as recommended in the guidelines should be encouraged. Published on behalf of the European Society of Cardiology. All rights reserved.
Authors: Aboubakr Mohamed Salama; Wael Ali Khalil; Manar Al-Zaky; Somia Hassan Abdallah; Nader Talaat Kandil; Ahmed Abdelsabour; Ahmed Mohammed Shaker; Mesbah Taha Hasanein; Giovanni Battista Luciani; Hassan M E Azzazy Journal: J Cardiovasc Transl Res Date: 2020-05-26 Impact factor: 4.132